The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated ...

Here's what investors need to know. On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had ...

The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.

Before Novo arrived as its owner, issues at the Bloomington facility caused a two-month delay for Eylea HD’s FDA approval decision in 2023. In November 2024, the FDA also found quality control lapses ...

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

Pharmaceutical companies behind weight loss and diabetes medication such as Ozempic are facing a lawsuit that could ...

New pill orforglipron was associated with a significant reduction in body weight and better cholesterol, triglycerides and blood pressure.

It faces more than 1,800 lawsuits consolidated in federal court in Pennsylvania and new claims emerging weekly, according to ...

The US Food and Drug Administration has approved the weight loss drug semaglutide, marketed as Wegovy, for the treatment of patients ... proportion of patients achieving resolution of MASH. The FDA ...